Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
58.8M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
36.9M
-
Shares change
-
+2.31M
-
Total reported value, excl. options
-
$376M
-
Value change
-
+$27M
-
Put/Call ratio
-
0.9
-
Number of buys
-
66
-
Number of sells
-
-37
-
Price
-
$10.19
Significant Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q4 2023
127 filings reported holding CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.9M shares
of 58.8M outstanding shares and own 62.65% of the company stock.
Largest 10 shareholders include MPM BioImpact LLC (7.65M shares), Blue Owl Capital Holdings LP (3.42M shares), FRANKLIN RESOURCES INC (3.28M shares), BVF INC/IL (3.2M shares), BlackRock Inc. (2.46M shares), VANGUARD GROUP INC (1.77M shares), BRAIDWELL LP (1.24M shares), AMERICAN INTERNATIONAL GROUP, INC. (1.24M shares), Nextech Invest Ltd. (1.22M shares), and CITADEL ADVISORS LLC (1.13M shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.